This presentation highlights EUROAPI’s CDMO services, focusing on their commitment to innovation, sustainability, and expertise. Mark MacDonald, Senior Business Development Manager CDMO at EUROAPI, explained how the company spun out from Sanofi in May 2022, with a strong focus on R&D and manufacturing of active pharmaceutical ingredients (APIs) and contract development and manufacturing organization (CDMO) services.
Thorsten Naumann, EUROAPI’s CDMO Peptide & Oligonucleotide Platform Leader, then explained how the company has multiple R&D and Manufacturing sites across Europe. EUROAPI sites can be found in the UK, France, Italy, Hungary, and Germany, with significant facilities in Frankfurt and Gera, Germany, focusing on oligonucleotides and peptides.
The company covers a range of modalities and technologies, including small molecule activities, biotechnology, fermentation, enzymes, and particle engineering, with extensive capabilities in spray drying and micronisation. The company dedicates 5-10% of its R&D personnel to innovation, focusing on green chemistry, analytical chemistry, process optimization, and continuous processes.
But as well as being dedicated to innovation, the company also wants its services to be applied sustainably. Therefore, EUROAPI aims for 100% renewable energy sources at all sites by 2025 and focuses on solvent recycling and minimization in peptide and oligonucleotide synthesis.
EUROAPI has decades of experience in peptide and oligonucleotide synthesis, including both solution and solid phase synthesis, and has recently expanded its capabilities with the acquisition of BianoGMP. The company is implementing new equipment, such as the Asahi Kasei synthesizer, to enhance their synthesis capabilities, ranging from milligram to kilogram scales.
This is combined with regulatory experience. The company has extensive capabilities in clinical development, analytical method development, validation, and regulatory filings, ensuring compliance with various standards.
Finally, Arjun Vijeta, an R&D Scientist at the company, presented a case study demonstrating the use of green solvents, process analytical tools (PAT), and SpinChem technology to make peptide synthesis more sustainable and efficient. This combined with real-time monitoring using PAT, allows for instant decision-making, deviation flagging, and optimization of synthesis processes, enhancing efficiency and quality.
